Clinical Trials Browser

Phase 1 × OTHER × Erlotinib Hydrochloride × Clear all

NCT00885066 2025-09-30

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00954226 2025-09-05

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Phase 1 Completed

Salivary Gland Neoplasms

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1 Completed

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT00954525 2025-05-02

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00254384 2024-07-05

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02942095 2023-04-18

Study of Ixazomib and Erlotinib in Solid Tumors

Phase 1 Completed

Neoplasm Metastasis

NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT01515137 2023-03-28

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01911507 2021-10-13

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02154737 2021-03-02

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01197170 2021-01-22

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Phase 1 Completed

Neoplasm Metastasis

NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 1 Completed

17 enrolled 12 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT00509431 2020-07-31

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00543504 2020-06-30

Bevacizumab in Multiple Phase I Combinations

Phase 1 Completed

Advanced Cancer

NCT03403049 2020-04-22

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00966472 2020-04-21

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT00581789 2019-11-19

Erlotinib and Sunitinib in NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02080078 2019-05-03

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Diarrhea

NCT01116336 2018-12-05

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

Phase 1 Completed

Head and Neck Neoplasms

NCT01967095 2018-11-13

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Phase 1 Completed

EGFR-Mutant Lung Cancer

NCT01103375 2018-08-01

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Phase 1 Terminated

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01561014 2018-07-02

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 1 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00565487 2018-05-21

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01998126 2018-04-02

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02342353 2018-02-27

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00998036 2017-12-13

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Phase 1 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00428194 2017-11-29

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Phase 1 Withdrawn

Uterine Cervical Neoplasms

NCT01650506 2017-08-30

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT00987766 2017-07-02

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Pancreatic Neoplasms

NCT00761345 2017-03-07

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Phase 1 Completed

27 enrolled 6 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00444015 2017-02-23

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01026844 2017-01-30

Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

27 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT01839955 2016-10-31

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00614653 2016-08-01

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01515969 2016-07-12

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01532011 2016-07-04

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Phase 1 Completed

Other solid neoplasm

Advanced Cancers

NCT00574366 2016-05-10

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00779389 2016-01-13

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Phase 1 Completed

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT02321293 2015-09-02

CURCUMIN

Phase 1 Unknown

Lung Neoplasms

NCT00126620 2015-07-23

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00895128 2015-07-13

Study of Erlotinib in Combination With Dasatinib

Phase 1 Completed

Advanced Cancer

NCT00895362 2015-07-13

Erlotinib in Combination With Cetuximab

Phase 1 Completed

Advanced Cancers

NCT00895687 2015-07-13

Study of Erlotinib in Combination With Bortezomib

Phase 1 Completed

Neoplasm Metastasis

NCT00903734 2015-07-13

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Phase 1 Completed

Neoplasm Metastasis

NCT00735306 2015-06-18

TART

Phase 1 Completed

12 enrolled 6 charts

Gastrointestinal

Pancreatic Neoplasms